Literature DB >> 3003445

Hydrochlorothiazide inhibits bone resorption in men despite experimentally elevated serum 1,25-dihydroxyvitamin D concentrations.

J Lemann, R W Gray, W J Maierhofer, H S Cheung.   

Abstract

We evaluated the effects of hydrochlorothiazide administration in relation to Ca balance, the PTH and vitamin D endocrine systems, acid-base balance, and bone. We studied six healthy men fed constant diets providing only 5.1 +/- 0.7 SD mmoles Ca/day. Three of the men were also given calcitriol, 0.5 microgram 6-hrly throughout their studies. All subjects were observed during 18 control days and then during 18 days of hydrochlorothiazide (HTZ) administration, 25 mg 12-hrly. Observations during control days 11 through 16 were compared to those during days 7 through 18 of HTZ administration, inclusively. Directional changes during HTZ did not differ among subjects not given or given calcitriol. For all six subjects, control net intestinal Ca absorption, serum 1,25-(OH)2-D concentrations, serum iPTH concentrations, and daily urine cAMP excretion averaged 0.5 +/- 2.2 mmoles/day, 162 +/- 51 pM, 4.3 +/- 2.2 microliter Eq/ml and 4.2 +/- 0.9 mumoles/day, respectively; none changed during HTZ. As expected, HTZ administration was accompanied by a fall in urinary Ca excretion, averaging -1.4 +/- 0.8 mmoles/day; P less than 0.01. HTZ administration was also accompanied by less negative Ca balances, averaging +1.6 +/- 1.0 mmoles/day; P less than 0.025, and by a fall in daily urinary hydroxyproline excretion averaging -0.13 +/- 0.09 mmoles/day; P less than 0.025. We interpret these data to indicate that HTZ administration is accompanied by an inhibition of bone resorption. HTZ administration also raised serum HCO3 concentrations by +2.7 +/- 0.5 mEq/liter; P less than 0.001 and blood pH by + 0.05 +/- 0.02 units; P less than 0.005.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3003445     DOI: 10.1038/ki.1985.223

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  8 in total

1.  Parathyroid hormone (PTH) regulates the sodium chloride cotransporter via Ras guanyl releasing protein 1 (Ras-GRP1) and extracellular signal-regulated kinase (ERK)1/2 mitogen-activated protein kinase (MAPK) pathway.

Authors:  Benjamin Ko; Leslie L Cooke; Robert S Hoover
Journal:  Transl Res       Date:  2011-08-18       Impact factor: 7.012

2.  Mitogenic action of hydrochlorothiazide on human osteoblasts in vitro: requirement for platelet-derived growth factor.

Authors:  K H Lau; X D Song; M Ochi; J E Wergedal
Journal:  Calcif Tissue Int       Date:  1996-12       Impact factor: 4.333

Review 3.  The association between drugs frequently used by the elderly and vitamin D blood levels: a review of observational and experimental studies.

Authors:  Anne Claire B van Orten-Luiten; André Janse; Rosalie A M Dhonukshe-Rutten; Renger F Witkamp
Journal:  Drugs Aging       Date:  2014-02       Impact factor: 3.923

4.  Mechanism of hypercalciuria in genetic hypercalciuric rats. Inherited defect in intestinal calcium transport.

Authors:  D A Bushinsky; M J Favus
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

5.  Role of proximal tubule in the hypocalciuric response to thiazide of patients with idiopathic hypercalciuria.

Authors:  Kristin J Bergsland; Elaine M Worcester; Fredric L Coe
Journal:  Am J Physiol Renal Physiol       Date:  2013-05-29

6.  Hydrochlorothiazide treatment of children with hypercalciuria: effects and side effects.

Authors:  G S Reusz; M Dobos; T Tulassay; M Miltényi
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

Review 7.  Drug-vitamin D interactions: a systematic review of the literature.

Authors:  Kim Robien; Sarah J Oppeneer; Julia A Kelly; Jill M Hamilton-Reeves
Journal:  Nutr Clin Pract       Date:  2013-01-10       Impact factor: 3.080

Review 8.  Evidence of Drug-Nutrient Interactions with Chronic Use of Commonly Prescribed Medications: An Update.

Authors:  Emily S Mohn; Hua J Kern; Edward Saltzman; Susan H Mitmesser; Diane L McKay
Journal:  Pharmaceutics       Date:  2018-03-20       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.